TRANSCELERATE BIOPHARMA INC (EIN 460886344) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2012

Legal Domicile

Principal Officer

JANICE CHANG

Phone

4845391230

Tax Period

2024-01-01 to 2024-12-31

TRANSCELERATE BIOPHARMA INC, founded in 2012, is a mid-sized nonprofit in the Medical Research sector that reported $38.6M in total revenue in fiscal year 2024. Revenue grew 13% year-over-year, indicating healthy expansion. The organization ran a surplus of $6.9M, a strong 18% operating margin.

Mission

IMPROVE THE HEALTH OF PEOPLE IN THE WORLD BY ENHANCING THE R&D OF INNOVATIVE THERAPIES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $37,402,000

Investment Income $1,193,799

Other Revenue $0

TOTAL REVENUE $38,595,799

Expense Breakdown

Grants Paid $0

Salaries & Benefits $9,759,153

Fundraising Expenses $0

Program Expenses $22,012,036

Other Expenses $21,980,786

TOTAL EXPENSES $31,739,939

Year-over-Year Comparison

	2024	2023	Change
Revenue	$38,595,799	$34,168,812	+0.1%
Expenses	$31,739,939	$32,521,149	0.0%
Net Income	$6,855,860	$1,647,663	+3.2%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,740,969

Total Directors

$1,104,805

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JANICE CHANG	CEO	40.00	Officer Director	$1,062,291	$42,514	$1,104,805
KATHRYN OWEN	CHAIR OF BOARD OF DIRECTORS	0.50	Director	$0	$0	$0
BADHRI SRINIVASAN	VICE CHAIR OF BOARD OF DIRECTOR	0.50	Director	$0	$0	$0
ELIAV BARR	BOARD MEMBER	0.50	Director	$0	$0	$0
DIETMAR BERGER	BOARD MEMBER	0.50	Director	$0	$0	$0
CHRIS CORSICO	BOARD MEMBER	0.50	Director	$0	$0	$0
ROB GOODWIN	BOARD MEMBER	0.50	Director	$0	$0	$0
LYKKE HINSCH GYLVIN	BOARD MEMBER (EFF 6/2024)	0.50	Director	$0	$0	$0
NARIMON HONARPOUR	BOARD MEMBER	0.50	Director	$0	$0	$0
CHRISTOPH KOENEN	BOARD MEMBER	0.50	Director	$0	$0	$0
MARIA KOUTSOPOULOU	BOARD MEMBER	0.50	Director	$0	$0	$0
BARI KOWAL	BOARD MEMBER	0.50	Director	$0	$0	$0
FABIO LIEVANO	BOARD MEMBER (EFF 11/2024)	0.50	Director	$0	$0	$0
IRIS LOEW-FRIEDRICH	BOARD MEMBER	0.50	Director	$0	$0	$0
CRISTIAN MASSACESI	BOARD MEMBER	0.50	Director	$0	$0	$0
ROBERT METCALF	BOARD MEMBER	0.50	Director	$0	$0	$0
MICHELLE ROHRER	BOARD MEMBER	0.50	Director	$0	$0	$0
MERDAD PARSEY	BOARD MEMBER	0.50	Director	$0	$0	$0
MOKASH SHARMA	BOARD MEMBER	0.50	Director	$0	$0	$0
TOM SENDEROVITZ	BOARD MEMBER (EFF 4/2024)	0.50	Director	$0	$0	$0
TADAAKI TANIGUCHI	BOARD MEMBER	0.50	Director	$0	$0	$0
TAKUKO YAMADA-SAWADA	BOARD MEMBER	0.50	Director	$0	$0	$0
ULI BROEDL	BOARD MEMBER (THRU 6/2024)	0.50	Director	$0	$0	$0
MARTIN HOLST LANGE	BOARD MEMBER (THRU 4/2024)	0.50	Director	$0	$0	$0
RAGAD ATTAR	BOARD MEMBER (EFF-5/24/ THRU-8/24)	0.50	Director	$0	$0	$0
ROOPAL THAKKAR	BOARD MEMBER (THRU 4/2024)	0.50	Director	$0	$0	$0
ALLISON CUFF SHIMOOKA	COO	40.00	Officer	$582,003	$54,161	$636,164
ANDREW LEE	TREASURER	0.50	Officer	$0	$0	$0
STEPHEN LIN	SECRETARY (THRU 11/2024)	0.50	Officer	$0	$0	$0
JENNIFER A BURGESS	VP, GLOBAL COMMUNICATIONS & ENGAGEMENT	40.00	Highest	$461,236	$44,362	$505,598
ANTHONY GARGES	HEAD OF FINANCE & ADMINISTRATION	40.00	Highest	$397,818	$47,267	$445,085
CARA L RINALDI	VP, PORTFOLIO MANAGEMENT	40.00	Highest	$417,189	$53,497	$470,686
JENEEN DONADEO	EXEC. PORTFOLIO DIRECTOR	40.00	Highest	$395,823	$33,953	$429,776
ROBERT DICICCO	VP, PORTFOLIO MANAGEMENT	40.00	Highest	$389,486	$66,267	$455,753

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$38,595,799	$31,739,939	$55,325,009	$6,855,860
2023	$34,168,812	$32,521,149	$48,107,662	$1,647,663
2022	$33,600,302	$34,262,372	$48,482,660	$-662,070
2021	$31,090,660	$33,180,341	$50,373,384	$-2,089,681
2020	$31,974,894	$28,107,965	$49,374,410	$3,866,929
2019	$27,979,345	$26,700,072	$45,613,199	$1,279,273
2018	$25,318,445	$30,891,037	$38,632,750	$-5,572,592

TRANSCELERATE BIOPHARMA INC